| Eylea (aflibercept intravitreal) / Bayer, Regeneron |
PULSOV, NCT04793100: Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections |
|
|
| Active, not recruiting | N/A | 60 | Europe | Ophthalmologic exam at inclusion and 12 months after CRVO, Treatment standardization with aflibercept | Fondation Ophtalmologique Adolphe de Rothschild, Bayer | Central Retinal Vein Occlusion | 03/25 | 03/25 | | |
ChiCTR2300073154: Study on the pathological mechanism of DME and related factors affecting treatment prognosis by MLC combined with cytokine detection in aqueous humor |
|
|
| Not yet recruiting | N/A | 60 | | Intraocular injection of aflibercept ;Intraocular injection of Ozurdex | Qingdao Eye Hospital of Shandong First Medical University; Qingdao Eye Hospital of Shandong First Medical University, Qingdao Eye Hospital Introduces Doctoral Funding | Diabetic Macular Edema | | | | |
NCT03941587: Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment |
|
|
| Active, not recruiting | N/A | 60 | RoW | Aflibercept + reduced fluence photodynamic therapy (RF-PDT), Eylea, Visudyne, Aflibercept + sham reduced fluence photodynamic therapy (RF-PDT) | Singapore National Eye Centre, National University Hospital, Singapore, Tan Tock Seng Hospital | Polypoidal Choroidal Vasculopathy | 07/24 | 07/24 | | |
SPECTRUM-US, NCT06398080: An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting |
|
|
| Not yet recruiting | N/A | 800 | NA | aflibercept 8 mg, EYLEA® HD | Regeneron Pharmaceuticals | Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Visual Impairment | 11/27 | 11/28 | | |
NCT05705258: A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity) |
|
|
| Recruiting | N/A | 75 | Japan | Aflibercept (Eylea, BAY86-5321) | Bayer | Retinopathy of Prematurity, Newborns, Infants | 04/26 | 03/27 | | |
| Enrolling by invitation | N/A | 80 | Europe | Aflibercept, Brolucizumab, early treat and extend (T&E) | Berner Augenklinik, medignition AG | Wet Age-related Macular Degeneration | 06/27 | 03/28 | | |
NCT04519619: Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG) |
|
|
| Recruiting | N/A | 480 | Japan | Aflibercept (Eylea, BAY86-5321) | Bayer | Neovascular Glaucoma | 06/27 | 06/28 | | |
NCT06075147: The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema |
|
|
| Recruiting | N/A | 2500 | Europe, Canada, Japan, RoW | Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Bayer | Visual Impairment, Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macula Edema (DME) | 10/27 | 01/28 | | |
